Literature DB >> 8045153

Continuous infusion of loop diuretics in the critically ill: a review of the literature.

S J Martin1, L H Danziger.   

Abstract

OBJECTIVES: a) To present the pharmacodynamic concepts behind the administration of loop diuretics via continuous infusion; b) to review the clinical trials and reports in critically ill patients that have described this method of drug delivery; and c) to discuss the data. DATA SOURCES: Review of MEDLINE and International Pharmaceutical Abstracts from 1966 to the present. STUDY SELECTION: Study design was not a factor in selecting literature for this review. All studies, case reports, and case series describing infusion of a loop diuretic are included. DATA EXTRACTION: Cited literature was found in peer-reviewed clinical or basic science journals. DATA SYNTHESIS: There is a pharmacodynamic basis for the use of a controlled infusion of the loop diuretics in critically ill patients requiring extensive diuresis. Animal and human volunteer studies have demonstrated a clear improvement in efficiency of diuresis by controlled infusion Clinical studies in critically ill patients have demonstrated an improved diuretic response with a controlled infusion. Adverse effects appear to be minimal, and the amount of drug required for effect is less than the required amount for bolus administration.
CONCLUSION: Administration of loop diuretics by continuous intravenous infusion may improve diuresis in critically ill patients who require prompt, controllable diuresis, or who demonstrate "diuretic tolerance" to conventional administration regimens. Despite few, well-designed studies using this method of administration in clinical practice, pharmacodynamic concepts support continuous infusion over bolus administration, including decreased dosage requirements, improved diuretic response and few adverse effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045153     DOI: 10.1097/00003246-199408000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

1.  Palliative and end-of-life care for patients with chronic heart failure and chronic lung disease.

Authors:  Miriam J Johnson; Sara Booth
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

2.  Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions.

Authors:  Laura Cuzzolin; Vassilios Fanos; Bernadette Pinna; Maria di Marzio; Monica Perin; Paola Tramontozzi; Paola Tonetto; Luigi Cataldi
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

Review 3.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Nonventilatory treatments for acute lung injury and ARDS.

Authors:  Carolyn S Calfee; Michael A Matthay
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

5.  Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery.

Authors:  Maria M J van der Vorst; Joana E Kist-van Holthe; Jan den Hartigh; Albert J van der Heijden; Adam F Cohen; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

Review 6.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 7.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

8.  Intermittent administration of furosemide or continuous infusion in critically ill infants and children: does it make a difference?

Authors:  J Klinge
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

Review 9.  Refractory heart failure.

Authors:  J B Young
Journal:  Curr Cardiol Rep       Date:  1999-05       Impact factor: 2.931

Review 10.  The rational use of diuretics in heart failure.

Authors:  Susan L Ravnan; Prakash C Deedwania
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.